UAB 1018/TBCRC 011; Bicalutamide for the Treatment of Androgen Receptor Positive (AR(+), Estrogen Receptor Negative, Progesterone Receptor Negative (ER(-)/PR(-), Metastatic Breast Cancer Patients: A Phase II Feasibility Study

Grant

Date/time Interval

  • July 1, 2009 - August 15, 2015

    • Awarded By

    Total Award Amount

  • 28600.00

    • Direct Costs

  • 26000.00

    • Sponsor Award Id

  • 2001102334

    • Contributor

  • Lisle Nabell M.D.   Investigator